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ABSTRACT. Live bacterial cells (LBC) are administered orally as attenuated vaccines, to 
deliver biopharmaceutical agents, and as probiotics to improve gastrointestinal health. However, 
LBC present unique formulation challenges and must survive gastrointestinal antimicrobial 
defenses including gastric acid after administration. We present a simple new formulation 
concept, termed Polymer Film Laminate (PFL). LBC are ambient dried onto cast acid-resistant 
enteric polymer films that are then laminated together to produce a solid oral dosage form. LBC 
of a model live bacterial vaccine and a probiotic were dried directly onto a cast film of enteric 
polymer. The effectiveness at protecting dried cells in a simulated gastric fluid (pH 2.0) 
depended on the composition of enteric polymer film used, with a blend of ethylcellulose plus 
Eudragit L100 55 providing greater protection from acid than Eudragit alone. However, although 
PFL made from blended polymers films completely released low molecular weight dye into 
intestinal conditions (pH 7.0), they failed to release LBC. In contrast, PFL made from Eudragit 
alone successfully protected dried probiotic or vaccine LBC from simulated gastric fluid for 2h, 
and subsequently released all viable cells within 60min of transfer into simulated intestinal fluid. 
Release kinetics could be controlled by modifying the lamination method.  
KEYWORDS  
Oral delivery; Enteric delivery; oral vaccines; probiotics; polymer film 
ABBREVIATIONS 
TPY broth, Tryptone-Phytone-Yeast broth; LBC, live bacterial cells; SIF, simulated intestinal 
fluid (pH 7.0); SGF, simulated gastric fluid (pH 2.0); CFU, colony forming unit; MLF, multi-
layer laminated film formulation; TF, thick laminated film formulation; EC, ethylcellulose; PFL, 
polymer film laminate; DoE, design of experiments. 
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Introduction 
Recently there has been a growing need to formulate and deliver increasingly complex 
biological therapeutics, from peptides, recombinant proteins and monoclonal antibodies to in 
vitro cultured eukaryotic cells, such as stem cells, and therapeutic live bacterial cells (LBC). 
Therapeutic LBC are being explored for various applications, each of which requires a tailored 
formulation in order to be delivered effectively. Attenuated live bacterial vaccines either injected 
(Bacillus Calmette-Guerin) or oral (Ty21a, Vivotif) can closely mimic natural infection and 
typically promote potent, long-lasting protective immune responses 
1
.Genetically engineered 
LBC vaccines can deliver heterologous antigens and induce an immune response to both the 
attenuated strain and the vector, thus protecting against a wide range of infections 
2
. Some orally 
administered therapeutic LBC are classed as probiotics, and are currently under intense 
development to modulate the gut microbiota in health and disease 
3,4
. Commensal enteric 
bacteria have also been genetically engineered to deliver biopharmaceutical agents such as IL-10 
to treat inflammatory bowel disease 
5
 or insulinotrophic proteins such as GLP-1 
6
. For all of 
these fields to advance, oral formulations are needed of LBC that offer the potential for 
controlled delivery of known doses of viable organisms, maintain stability for long-term storage 
preferably without refrigeration, and allow cost-effective manufacture. 
For LBC to be therapeutically active, cells must be kept alive during formulation and delivery. 
For example, dead bacteria are less immunogenic than live cells 
7,8
, and although some health 
benefits have been suggested for dead probiotic cells, only live cells can replicate within and 
colonize the colon 
9
. Mammals have evolved a highly antimicrobial gastrointestinal (GI) tract as 
a defense against food- and water-borne microbial enteric pathogens, and LBC administered by 
the oral route confront multiple challenges after ingestion, including gastric acid, enzymatic 
degradation, antimicrobial peptides, bile acids, and secreted innate and adaptive 
immunoglobulins. A successful oral formulation of LBC typically requires enteric delivery to 
protect from the strong acidic environment in the stomach and target release into the small 
intestine or beyond, depending on the therapeutic target site. Thus LBC vaccines may be targeted 
to the ileum rich in Peyers patches, whereas some probiotics are targeted to the large intestine to 
modulate the intestinal microbiota. Enteric coatings are typically acid-insoluble films that stay 
intact during transit of solid oral doses through the stomach and subsequently dissolve and 
release contents as pH increases in the intestine. Tablets and granules are the most common solid 
oral enteric formulations but capsules can also be effectively enterically coated 
10
. Enteric 
coatings can be used for three distinct purposes: firstly to protect gastric mucosa from irritant or 
toxic active pharmaceutical ingredient (API), secondly to deliver an API to a lower GI site, and 
thirdly to protect acid-labile API from gastric acid (e.g. omeprazole). Protection of gastric 
mucosa and intestinal delivery are both achieved by the enteric film layer remaining intact in 
acid preventing dose disintegration, whereas API protection is achieved by the enteric polymer 
film blocking ingress of acid into the solid formulation. Although most enteric polymers are acid 
insoluble, they do typically swell in acid with the degree of swelling and permeability of enteric 
polymer films varying dependent on polymer composition 
11,12
. LBC formulations must achieve 
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delivery to an intestinal site but protection from acid toxicity is also vital given the high 
sensitivity of dried bacteria to acid 
13,14
. Research in enteric delivery has developed a spectrum of 
approved enteric polymers coupled to a broad range of coating methodologies. Further 
improvement of pharmaceutical polymer properties can be achieved by blending polymers to 
combine distinct desired properties and provide endlessly tunable coating performance 
12
. For 
example, improved protection of API from acid was achieved by blending enteric polymers with 
insoluble polymers 
11,15,16
. 
LBC have been formulated using enteric coated tablets 
17
, capsules 
18
 and granules 
19
. 
Protection from acid using co-administration with buffer solutions has also been used 
18
, and 
microencapsulation has been explored for acid protection and controlled delivery 
20,21
.In all cases 
drying is required to preserve cell viability during long term storage. However, the dehydration 
process can damage cells through osmotic and oxidative stress and also denaturation of 
biomolecules 
22
. This can be prevented by sugar glasses formation, an effective and well 
understood approach to stabilization of biomacromolecules during drying
23
. Although much 
work has focused on freeze-drying, many bacteria and related complex biological payloads are 
more robust when freezing is avoided 
24
. A continuous, ambient temperature drying process 
would also be more cost effective than freeze drying, where major costs are incurred by the slow 
batch turnaround and high cost of large scale freeze drying equipment. Other drying methods, 
including spray, fluidized bed, foam, vacuum and air convective drying have been explored for 
the industrial mass-production of dried microorganisms 
25
. Perhaps the simplest ambient 
temperature drying method is to spread material in a thin film to provide a large surface area for 
evaporation. Ambient temperature drying on a flexible belt is used for continuous, scaleable 
drying of sensitive food products 
26,27
. Ambient temperature drying onto polymer films has 
historically been used for preservation and storage of microbial reference samples 
28
, but 
sophisticated film drying methods has recently been adopted for advanced biotechnology 
applications ranging from biocatalysis and biosensing to food technology. Flickinger and co-
workers developed a sophisticated and robust method for painting and printing live bacteria, 
using polymer latex plus nontoxic adhesive films to permanently entrap cells, preserving cell 
viability and metabolic activity on surfaces at ambient temperatures 
29
.Others have incorporated 
live lactic acid bacteria into an edible, flexible casein film, with high cell survival after drying 
and storage, as an antimicrobial meat packaging material 
30
. 
Here, we propose a novel approach to oral formulation of LBC which exploits the benefits of 
ambient film drying technology and inspired by a novel yet simple and powerful web 
formulation technology recently developed for oral delivery of small molecule APIs 
31,32
. In the 
Sticky Web approach, a carefully metered dose of API in dry powder form adheres to an 
adhesive patch printed on a polymer film web. We propose that a cast film of enteric polymer 
can be used as a web for drying LBC allowing continuous and scaleable ambient temperature 
lyophilization and combination with a protective enteric film in a single unit operation (Figure 
1a). The web comprising dried cells on enteric polymer film can then be directly laminated using 
edible adhesives to produce an oral solid dosage form (Fig 1b). The resulting polymer film 
laminate (PFL) formulation can be made using a variety of lamination methods, polymers and 
film thicknesses to provide fully customized LBC delivery. Here, we investigate if bacteria can 
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be directly dried onto enteric polymer films, if this material is sufficient for protecting dried 
bacteria from gastric acid, and if a prototype oral PFL formulation can be used to deliver live 
vaccine and probiotic bacteria in simulated gastrointestinal fluids. 
Materials and Methods 
Materials. Eudragit L100 55 (Eudragit L, methacrylic acid-ethyl acrylate copolymer 1:1), was a 
kind gift from Evonik, Germany. Triethyl citrate, LB broth and LB agar were from Sigma 
Aldrich (Gillingham, UK). Dow Methocel E15 LV Hydroxypropyl methylcellulose (HPMC) 
(28-30% Methoxyl, 7-12% Hydroxypropyl content, 12-18mPAs at 2% in water) was kindly 
supplied by Colorcon (UK). Bifidobacterium breve NCIMB 8807 was obtained from the U.K. 
National Collection of Industrial and Marine Bacteria (NCIMB). Ethyl cellulose (ethoxyl content 
48%, 8 to 11 cPs at 5% w/v in 80:20 toluene/ethanol) was from Acros Organics, Belgium. 
Wilkins-Chalgreen (WC) anaerobe agar was from Oxoid (Basingstoke, UK). Water Blue dye 
was purchased from Fluka, UK. 
Preparation of polymer films. Polymer films were cast from solution by solvent evaporation 
as follows. Eudragit L100 55(12.5% w/v), Ethylcellulose (EC) (5% w/v) or a blend of 
Eudragit:EC (with Eudragit to ethylcellulose ratio of 25:75, 50:50 or 75:25) were fully dissolved 
with stirring in ethanol and triethyl citrate plasticizer added to 25% w/w based on polymer mass. 
HPMC (2% w/v) was dispersed in deionized water heated to 90ºC and then cooled with stirring 
to ensure complete dissolution following manufacturer recommended protocol. Polymer 
solutions were cast by solvent evaporation in 90mm diameter Petri dishes with the volumes 
adjusted (7.5-50mL) to achieve the desired dry film thickness, measured using a micrometer at 5 
points on each square of film used to dry LBC, with cast film thickness ranging from 60µm to 
200µm. Thicker films (up to 1mm) used to make spacers between laminated dried cell spots (Fig 
1b) were cast from higher volumes. Films were dried at room temperature for 3 days or 40 ºC for 
2 days. Prior to making bacterial formulations, films were sterilized by UV irradiation for 15 
minutes and thereafter handled aseptically. With enteric polymers complete solvent removal was 
important to prevent toxicity of the ethanol to dried LBC, and thermogravimetric analysis was 
performed on cast film samples to confirm absence of solvent. 
Acid permeability of enteric polymer films. Two assays were used to compare the acid 
permeability of films cast from Eudragit alone or Eudragit:EC (50:50) blend. Swelling of films 
in acid was monitored to determine if acid could penetrate into polymer films. Polymer films 
pieces (1.5 x 1.5 cm) were immersed in 30 mL SGF solution (0.1M HCl) at 37ºC with stirring. 
To measure film dissolution samples were placed in a SIF solution of phosphate buffer (pH 7.0) 
at 37ºC with stirring. In both cases, films were weighed before immersion and at the indicated 
timepoints after removing excess fluid on filter paper. Water gain was calculated as ((wet mass - 
dry mass)/ dry mass) x 100 and expressed as swelling % w/w. A Franz diffusion cell was also 
used to determine if acid could diffuse through cast enteric polymer films. Films cast from 
Eudragit L100 55 or Eudragit:EC (50:50) blend were compared with a control dialysis 
membrane (12-14000Da MWCO, Medicell International, UK). To prevent film dissolution 
which will occur with Eudragit at pH greater than 5.5, films were equilibrated in deionized water 
with the pH adjusted to 4.2 prior to mounting in the diffusion cell, and the acceptor chamber was 
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filled with deionized water at pH 4.2. The top donor chamber was loaded with 0.1M HCl (pH 
2.0) and the lower acceptor chamber was continually stirred and pH monitored at indicated 
timepoints up to 6h. 
Ambient temperature drying of therapeutic bacteria onto polymer films. Two model 
therapeutic bacterial strains were selected: the anaerobic Gram positive model probiotic 
Bifidobacterium breve (strain NCIMB 8807) and the aerobic Gram negative model mouse live 
attenuated vaccine Salmonella Typhimurium strain SL3261. Single colonies of B. breve from 
Wilkins-Chalgreen anaerobe agar were inoculated into 10mL trypticase-phytone-yeast (TPY) 
broth, adjusted to optimal starting density and incubated anaerobically at 37˚C for 21-22 hours to 
obtain cultures with an OD600 of 2.0 corresponding to late log phase/initial stationary phase of 
growth. Single colonies of S. Typhimurium SL3261 from LB agar were inoculated into 10mL 
LB broth, adjusted to optimal starting density and incubated at 37ºC for 18-20 hours to obtain 
cultures with an OD600 of 2.0 corresponding to late log phase/early stationary growth phase. 1 
mL aliquots of cells were harvested in microcentrifuge tubes by centrifugation (10000 rpm, 10 
min), supernatant removed and cell pellets resuspended in 100 µL sterile lyoprotectant mix of 
deionized water with 40%w/v trehalose. Measured volumes of the resultant cell slurry were 
either placed dropwise in spots on cast polymer films, or spread over 1.5 cm
2 
films. LBC on 
films were dried in a desiccator for at least 18 hours; this time was chosen because in kinetic 
analysis of the drying process after 16h no further water loss was measurable. Residual water 
content of samples of cells dried onto polymer films was determined using thermogravimetric 
analysis (TGA), using 5ºC /minute ramp rate from 25ºC to 200ºC in a TA instruments Q500 
Thermogravimetric Analyzer. Initial experiments were conducted at room temperature, however 
it was noted that laboratory temperature varied sufficiently to significantly alter cell recovery 
post drying and dried cell phenotype; subsequently all drying was completed in environmental 
chambers with controlled drying temperature. Drying temperature for experiments presented in 
Figures 2, 5 and 7 was 20ºC and for experiments presented in Figure 4 drying temperature was 
26ºC. Temperature and relative humidity during drying were monitored using a USB datalogger 
(Omega, UK), and stayed within ±1ºC from indicated drying temperature with relative humidity 
staying between 4-6%. 
Viable cell counting. Live cell recovery was evaluated using serial dilution of samples and 
agar plate colony counting at all steps: before and after drying onto polymer films, and during 
acid resistance and dissolution tests. Serial 3-fold dilutions were made in TPY or LB broth in 
sterile 96-well plates with a multichannel pipettor. In detail, 10 µL spots dried onto polymer film 
were rehydrated in 10 mL of rehydration medium, of which 50 µL samples were transferred into 
100 µL of broth, to complete 16 serial 3-fold dilutions and 5 µL samples of each dilution were 
then spotted onto square plates of Wilkins-Chalgreen anaerobe or LB agar to give dilution 
factors of 10
5 
to 10
10
. To determine lowest detection limit of 10
3
 CFU/mL 10µL samples was 
also plated directly from rehydration medium. Samples were dried for 10-15 minutes prior to 
incubation. B. breve plates were incubated anaerobically at 37 ºC for at least 48 hours and S. 
Typhimurium plates were incubated aerobically at 37 ºC for at least 24 hours. Colonies were 
counted and final viability expressed as colony forming unit per mL (CFU/mL) calculated 
relative to the initial volume cell slurry. To follow viable cell recovery after drying and exposure 
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to simulated GI conditions viable cell counts were expressed relative to the initial volume of cell 
slurry before drying.  
Acid protection after direct drying onto enteric polymer films. Cells were dried onto the 
enteric polymer Eudragit or a blend of Eudragit and ethylcellulose as above, and resistance to 
acid tested by pipetting 40µL of SGF (0.1M HCl) on the film surface on the opposite side to the 
dried cells; as a control the same volume of SGF was pipetted directly onto the cell spot on the 
film (see diagram in Figure 4). After 2 hours of exposure to acid the viability was determined by 
complete dissolution into buffered peptone water and compared to the viability of replicate 
samples directly released into buffered peptone water. 
Preparation of polymer film laminate oral formulations. To produce encapsulated polymer 
film laminate (PFL) formulations, cells were dried onto 1.5cm
2
 Eudragit or Blend polymer film 
squares and two complete squares were laminated either side of a single layer of thick film or 
multiple layers of film containing a central hole of an equal size to the dried cell spot (Figure 
1b), thereby encapsulating the dried cells. Prototype formulations were produced using either, 
double sided adhesive tape or rapid setting, non-toxic cyanoacrylate adhesive to seal the multiple 
polymer film layers around the dried cells or dye. To produce thick film (TF) formulations 
(Figure 1b), 10µL spots of LBC slurry were dried onto Eudragit polymer film pieces of 1.5 cm
2
 
as described above. A square of thicker cast polymer film (1 mm) was prepared with a central 
hole punched of an equal size to the dried cell spot (4mm diameter), and cyanoacrylate adhesive 
used to seal cell-bearing polymer film squares face to face on either side of the thick film, 
enclosing the dried cells. Multi-Laminate film (MLF) formulations (Figure 1b) were produced 
from two film squares with dried cell spots separated face-to-face around 10 layers of thin (100 
µm) polymer film with punched holes; the 10 thin layers with punched holes were laminated first 
with cyanoacrylate adhesive, and after curing for 1h the outer two film squares were sealed with 
cyanoacrylate adhesive. In all cases, during sealing laminates were compressed with moderate 
pressure for 1h to allow the adhesive to cure fully prior to in vitro dissolution tests. In some tests, 
Water Blue dye was incorporated instead of dried cells to study small molecule release from 
laminates; 1.5 mg of dye powder was encapsulated within the laminate formulation. 
Protection and live cell release from polymer film laminate formulation in simulated 
gastrointestinal conditions. Prototype PFL formulations were immersed in simulated gastric 
fluid (SGF) (pH 2.0, 20 mL of 0.1 M HCl) at 37ºC for 2 hours with orbital shaking at 100 rpm. 
Samples were taken at 0, 1 and 2 hours and live cell release counted, although PFL formulations 
remained intact in SGF with no dissolution or cell release detected by visual inspection. After 2 
hours in SGF, formulations were transferred into 10 mL simulated intestinal fluid (SIF) (0.68% 
w/v monobasic potassium phosphate and 1.5% w/v peptone at pH 7.0) and incubated at 37ºC 
with orbital shaking at 100 rpm. Samples were taken and live cell release determined at 0, 1, 2 
and 3 hours after transfer from SGF. For each experiment identical samples of LBC dried onto 
films but not laminated were incubated for 20 min in SIF and live cell recovery counted to 
determine the post-drying viable cell number prior to making and testing PFL formulations.  
Kinetics of dissolution and dye release from polymer film laminates. Prototype PFL 
formulations containing Water Blue dye were immersed in SGF (pH 2.0, 20 mL) for 2 hours at 
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37ºC, with shaking. Samples were taken from this solution at 0, 1 and 2 hours and dye 
concentration measured spectrophotometrically at =580nm. After 2 hours, formulations were 
transferred into SIF (pH 7.0, 10 mL) and incubated at 37ºC with orbital shaking at 100 rpm. Dye 
concentration was measured at the indicated times and percentage of dye released calculated. 
Statistical analysis  
Data and results are reported as mean with error bars indicating standard deviation. Statistical 
evaluation of comparing the significance of the difference in viability between the means of two 
groups was performed using a two-tailed unpaired Student’s t-test; a value of p < 0.05 was 
accepted as significant. 
 
Results and Discussion 
Drying bacteria onto enteric polymer films. Although we envisage that cells can be 
continuously dried onto a polymer web (Figure. 1a), our focus in this study was to determine the 
feasibility of successfully drying bacteria onto a cast enteric polymer film, and protecting from 
acid. Initial experiments therefore investigated the conditions needed for effective ambient 
temperature drying of vaccine and probiotic LBC onto films of pharmaceutical polymers 
acceptable for oral delivery. Cells of a model probiotic strain of B. breve were mixed with a 
protectant mix containing the lyoprotectant trehalose and dried at ambient temperature onto films 
cast from pharmaceutical polymers. A drying time of 16 - 20 hours was established by 
completing detailed analysis of the kinetics of drying by monitoring sample mass at hourly 
intervals. These studies showed that > 95% water loss was achieved by 16h, with no significant 
further water loss at 20h and beyond. After drying, the residual water content of 3.32 ± 0.53%, 
(n=3) of the dried cells was determined by thermogravimetric analysis. Two methods were 
directly compared to ensure controlled and even distribution of cells onto cast films prior to 
drying: either a measured volume of cell slurry was spread over a marked area of polymer film, 
or drops of the same cell slurry in identical excipient were dried without spreading to produce a 
‘cell spot’ of known cell dose. Although the surface area after spreading was 3 times higher than 
cell spots (2.25 vs 0.8 cm
2
) which would likely result in a faster drying rate, both samples of 
dried cells were tested for viable cell recovery at the same timepoint and no difference in 
viability on HPMC films after drying was observed between these methods (Figure 2a). 
Subsequent experiments were therefore performed using dried cell spots of fixed volume and 
thus known input LBC number. Acceptable viability post-drying was achieved onto enteric 
polymer films cast from Eudragit alone or a blend of Eudragit:EC (50:50 w/w), as well as HPMC 
films (Figure 2b). The highest live cell recovery was achieved onto HPMC films with a cell loss 
of 0.5 log, with drying onto enteric polymer films giving slightly greater loss of viability of up to 
1 log (Figure 2b). 
Previous work has already established that drying LBC can reduce cell viability to an extent 
that depends on the drying process, cell strain and growth stage, and lyoprotectant excipients 
25,33
. In pilot experiments with B. breve, the loss in cell viability observed after drying onto cast 
polymer films ranged from 0.5 log loss (e.g. Fig 2) to >3 log loss. The excipient in which cells 
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were resuspended prior to drying and the drying temperature were the variables which had the 
greatest influence over post-drying viability. The excipient trehalose was chosen for experiments 
performed here as when compared to other excipient mixes (e.g. buffer or medium alone) it 
provided the most consistent live cell recovery in a range of different drying conditions. 
Increasing the drying temperature from 20ºC to 35ºC resulted in lower post-drying viability. For 
example, when dried at 20ºC between 1.2-1.5 log loss of viable cell count was observed; in 
contrast, at 35ºC from 2.6 to 3.4 log loss was observed. The surface onto which LBC were dried 
also had a moderate but significant influence over loss during drying, with drying onto Eudragit 
and Eudragit:EC blend films resulting in greater loss of viability than drying onto HPMC (Figure 
2b). Similar viable cell recovery was observed after LBC drying onto films cast from other 
pharmaceutical polymers including alginate and Aqoat™ HPMC-AS (data not shown).  Further 
investigations are required to understand how the polymer film surface influences LBC loss 
during drying.  
One main aim of drying therapeutic LBC is to improve product stability, since in general dried 
microorganisms can retain viability for longer than liquid cultures. Although many factors affect 
the stability of dried LBC and the focus of this study was not to achieve thermostability, it is 
important that dried cells had residual moisture below 10%,
34,35
 as observed by TGA. However, 
the optimum residual moisture content for stability varies with the composition of the fluid in 
which organisms are dried, with the storage atmosphere, the species and strain, and the 
physiological state of the organisms,
36
 and so optimum water content for longest product stability 
will need to be individually determined for each LBC formulated. 
Acid permeability of enteric polymer films. Published studies 
11,12
 have established that a 
hydrophobic polymer such as EC can be blended with enteric polymers such as Eudragit to 
increase the protection of an API from acid. Protecting dried bacteria from gastric acid is 
especially important here because of their increased acid sensitivity compared to cells in culture 
13
, combined with the direct contact between dried cells and the enteric film. We thus compared 
films cast from both Eudragit and a Eudragit:EC (50:50) blend for acid permeability. The 
methacrylic acid : ethyl acrylate copolymer Eudragit L was used, which dissolves above pH 5.5. 
When enteric polymer films were immersed in SGF, they remained intact but swelling and mass 
gain was observed indicating a degree of acid permeability. As expected 
11,15,16
 the degree of 
swelling in SGF was lower and slower with Eudragit:EC than Eudragit alone (Figure 3a). 
Although swelling was observed with both Eudragit and Eudragit:EC blend films in SGF 
indicating penetration of acid into the polymer, this assay did not indicate whether acid can 
penetrate fully through the films. The penetration of acid through films was therefore tested 
using a Franz diffusion cell. To prevent rapid dissolution of the film, the acceptor chamber was 
filled with water acidified to pH 4.2. The donor chamber was filled with SGF (pH 2.0), and as 
expected a control cellulose dialysis membrane allowed acid to rapidly permeate, with the 
acceptor chamber pH equilibrating to pH 2.5 by 4 hours (Figure 3b). In contrast, the acceptor pH 
remained at pH4.2 with either Eudragit or Eudragit:EC films (Figure 3b), demonstrating the acid 
impermeability of these films. No acid permeation was observed through Eudragit and 
Eudragit:EC blend films ranging in thickness from 75 – 350 µm (data not shown). Having 
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measured acid permeability, films were then tested at pH 7.0 to check dissolution and release in 
intestinal conditions. Eudragit films fully dissolved within 30 min immersion in SIF pH 7.2 
(Figure 3c),but Eudragit:EC blend films gained weight and swelled, reaching 5x starting weight 
by 6 hours (Figure 3c), gaining characteristics of a hydrogel. This indicated that the Eudragit had 
leached out of the film leaving a porous network of insoluble EC, and raised the possibility that 
blended films with increased acid impermeability may not be able to release LBC.  
Protecting dried LBC from acid with enteric polymer films. Having established that 
Eudragit:EC blend films were less acid permeable than Eudragit alone, but that both films were 
equally able to block acid diffusion, the ability of the two enteric films to protect dried LBC from 
direct acid exposure was compared. In these experiments, cells were dried onto enteric films at 
an increased temperature of 26ºC, resulting in greater cell loss on drying than that observed in 
previous experiments where drying was conducted at 20ºC (compare Figures 2 vs 4). To avoid 
this increased loss of viability on drying, in subsequent experiments (see Figures 5 and 7 below) 
a drying temperature of 20ºC was used. 
When dried cells were exposed directly to SGF, viability rapidly dropped below the limit of 
detection of <10
3
 CFU/mL representing a >10
5
-fold loss. In contrast, when acid was placed on 
the opposite side of films for 2 hours, followed by determination of remaining viable cell counts, 
significant numbers of viable cells were recovered (Figure 4), confirming that enteric polymer 
films are sufficient to provide a degree of protection from acid. As expected from the Franz 
diffusion cell study, both enteric films protected dried cells when SGF was placed onto the film 
surface opposite the dried cells for 2 hours (Figure 4). However, the cell recovery seen after 2 
hours acid exposure was greater with the Eudragit:EC blend than Eudragit alone, indicating that 
the blended polymer film provided improved protection from acid in agreement with the 
swelling results (Figure 3a) and prior work 
11,15,16
. Indeed, with the Eudragit:EC blend less than 
0.5 log reduction in viable cell recovery was observed after 2 hours exposure of the film to SGF. 
In contrast, a nearly 2 log reduction in viable cell recovery was seen with pure Eudragit films, 
suggesting that the observed swelling in acid (Figure 3a) may have also allowed sufficient acid 
to permeate through films to adversely affect the viability of cells dried onto Eudragit films. It is 
possible that the increased viable cell recovery with Eudragit:EC blend over Eudragit alone films 
could be attributable to increased release of viable cells, rather than simply increased protection 
from acid. However, both films released similar viable cell numbers when directly exposed to 
SIF, with the small apparent increase in cell release from Eudragit:EC blend films not being 
found to be statistically significant (figure 4; p>0.05). 
We conclude that cells dried directly onto enteric polymer films can be protected from acid. 
Significant cell recovery after two hours acid exposure was achieved, with an Eudragit:EC blend 
offering better acid protection than Eudragit alone. 
Prototype Polymer Film Laminate oral formulations. Live bacterial cells were dried onto 
enteric polymer films and prototype solid oral formulations illustrating the Polymer Film 
Laminate concept (Figure 1) were made and tested. To evaluate the suitability of PFL made from 
enteric polymer films for protecting live dried LBC from gastric acid and subsequently releasing 
viable cells into the intestine, prototypes were tested in simulated gastrointestinal conditions (2 
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hours in SGF pH 2.0 and 3 hours in SIF pH 7.0) and cell viability sampled at regular timepoints. 
Prototype PFL containing a single 10µL spot of dried cells with a viable cell density equivalent 
to 10
9
 CFU/mL (i.e. approximately 10
7 
CFU B. breve per dose) were made by laminating either 
Eudragit or Eudragit:EC blend films together using layers of adhesive tape with a central hole 
cut matching the dried cell spot (Figure 1b). After 2 hours of exposure in SGF pH 2.0, both 
Eudragit or Eudragit:EC blend formulations were intact and no cells released. Importantly, 1 
hour after transfer into SIF pH 7.0, the Eudragit PFL formulations had fully dissolved and cell 
recovery equivalent to the starting cell density of 10
9
 CFU/mL was observed, indicating no loss 
in cell viability after 2h in SGF at pH 2.0 (Figure 5). In contrast, after 3 hours in SIF pH 7.0 the 
Eudragit:EC blend PFL became highly swollen but intact with no disruption of the polymer 
matrix, and no viable cells were recovered in SIF pH 7.0 (Figure 5). This was surprising 
considering the improved protection from acid seen with film alone (Figure 4). Indeed, when 
swollen Eudragit:EC blend PFL samples were mechanically disrupted significant numbers 
(>2x10
7
 CFU/mL) of viable cells were recovered (data not shown) suggesting that the absence of 
viable cell recovery was not due to loss of cell viability but instead represented a failure to 
release LBC. 
To determine if the Eudragit:EC films were capable of releasing low molecular weight 
molecules into SIF, dye release studies were completed with PFL made from Eudragit or 
Eudragit:EC blend loaded with Water Blue dye instead of dried LBC, and exposed to SGF 
followed by SIF. In contrast to the lack of release of LBC from the Eudragit:EC PFL prototype, 
complete release (>90%) of Water Blue dye was seen from both enteric polymer formulations 
within 1 hour of transfer from SGF into SIF (Figure 6) confirming that although the Eudragit:EC 
PFL does not fully dissolve at pH 7.0, it can still release low molecular weight contents. In 
previous work where Eudragit:EC film coatings were applied to tablets, rapid release was 
achieved, possibly due to disintegration of the tablet following swelling at elevated pH 
37
.  
We conclude that although blending enteric polymers with ethylcellulose can increase 
protection from acid and is suitable for film coating tablets and low molecular weight APIs, the 
blended film is unsuitable for LBC delivery in PFL. This observed poor release from PFL could 
be attributed to a number of reasons, including the large size of bacterial cells or interactions 
between bacterial cells and EC. Although electrostatic interactions between neutral (EC) and 
negatively charged (Eudragit) polymers with negatively charged bacterial cells is unlikely, but 
undissolved EC could bind cells through hydrophobic interactions. Further studies of the 
porosity of Eudragit:EC films are required to fully understand the range of APIs that could be 
successfully released from formulations formed from this polymer blend. 
Surprisingly, although in acid protection experiments significant cell loss – of up to 100-fold 
compared to controls samples not exposed to acid – was observed with Eudragit films (Figure 4), 
complete recovery of identical viable cell counts to control samples was seen from Eudragit PFL 
(Figure 5) after 2 hours exposure to SGF in both experiments. There are two explanations of the 
improved protection from acid seen with prototype PFL compared to the previous experiments 
where acid was simply pipetted onto the opposite side of Eudragit films to dried cells. Firstly, it 
is possible that dried cells within PFL are better sealed from acid than the film pieces exposed to 
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acid without lamination. Secondly, in acid protection studies (Figure 4) cells were dried at 26ºC 
whereas in contrast prototype PFL formulations were made from cells dried at a lower 
temperature of 20ºC (Figure 5). This temperature was chosen to reduce cell loss during drying, as 
when drying temperatures were directly compared it was discovered that drying at the an 
elevated temperature of 35ºC gave 2.6 to 3.4 log loss of viability, in contrast to drying at 20ºC 
where loss was 1.2 to 1.5 log. Further preliminary studies suggested that increased drying 
temperatures increase the sensitivity of dried cells to acid as well as reducing viability after 
drying (Figures 4 vs 5 and unpublished observations).  
In conclusion, the Eudragit PFL is capable of efficiently protecting dried live probiotic bacteria 
from 2h immersion in SGF. Although the drying process always gave a loss close to 1-log 
reduction in viable cell number, the overall delivery efficiency considering all process steps is 
adequate and compares well with other formulations of probiotic cells 
20,38
. 
Controlled probiotic and vaccine release from enteric PFL formulations. Building on the 
observation that live cells are protected from acid and rapidly released from Eudragit PFL 
formulations, further PFL were made with varying bacterial payload, film thickness, type of 
adhesive and method of lamination. Firstly, the effect of PFL construction on protection from 
SGF and release in SIF was investigated. PFL containing B. breve dried onto Eudragit films were 
laminated using adhesive tape or non-toxic cyanoacrylate adhesive. The use of multiple thin 
spacers laminated between cell-loaded films was compared to a single thick spacer layer. In all 
cases, endpoint cell recovery was excellent, with cell recovery 3 hours post transfer into SIF 
identical to that seen when replicated samples of cells dried onto films were directly incubated 
for 20 minutes in SIF without lamination, indicating no loss of viability after 2 hours immersion 
in SGF (Figure 7a). However, different release kinetics were observed depending on the 
lamination method and adhesive used. Thus although complete cell release was seen after only 
60 minutes in SIF with PFL produced from multiple layers of thin film laminated with adhesive 
tape, or when thick Eudragit films were laminated using edible adhesive, in contrast complete 
cell recovery was delayed until 3 hours after transfer into SIF when multiple layers of thin films 
were laminated with edible adhesive (Figure 7a). This delay in release is most likely to be caused 
by the increased amount of adhesive present with the MLF formulations that appeared to slow 
down the film disintegration in SIF. This excess of adhesive with prototype MLF formulations 
was caused by the manual lamination method and could be overcome by accurately metering the 
quantity of edible adhesive used to assemble PFL. 
Although experiments with the model probiotic B. breve demonstrated the concept of direct 
enteric formulation of dried cells, bacteria vary significantly in their response to drying and 
resistance to gastrointestinal microbicides. Therefore similar PFL formulations were produced 
using the model live bacterial vaccine Salmonella enterica subspecies Typhimurium strain 
SL3261. The viability of S. Typhimurium after drying onto Eudragit films was excellent when 
measured after direct release in SIF, with less than 0.5 log loss post-drying (Figure 7b). In 
contrast, when directly exposed to SGF pH 2.0 no viable cells were recovered, as expected given 
the known sensitivity of this strain to pH <3 (data not shown and 
13
). Importantly, when PFL 
were made from S. Typhimurium dried onto Eudragit films following 2 hours immersion in SGF, 
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followed by transfer to SIF, complete viable cell release was achieved (Figure 7b).When 
Eudragit film thickness was varied, the kinetics of vaccine cell release could be modified, with 
100µm films releasing total LBC load within 60 min of transfer into SIF in contrast to 165µm 
films which delayed release until 2-3 hours after transfer (Figure 7b). 
By varying film thickness and PFL lamination method, controlled enteric release of viable 
LBC from a solid oral formulation is feasible. The recovered relative cell density of 10
10
 
CFU/mL (expressed relative to the initial cell volume) from prototype PFL produced containing 
a single spot dried from 10µL cells indicates a live cell dose of 10
8
 viable cells per formulation, 
and confirms the feasibility of producing PFL with standard doses of LBC, where typical oral 
doses of both live bacterial vaccines and probiotics range from 10
8
 to 10
10
 viable bacteria 
18,39,40
. 
Increasing LBC dose beyond 10
8
 can be achieved simply by increasing the number of dried cell 
spots in the PFL, or by increasing the cell density in the slurry, the volume of slurry and the area 
of the dried cell spot. The post-drying viability, cell dose delivered, and product stability of 
formulated dried LBC is already known to depend upon a wide range of variables, including cell 
species and strain, culture conditions, drying conditions and excipients used
33
, for this reason it 
will be essential for systematic multivariate DoE optimization to be used to develop specific 
formulations using this new process. 
PFL represents an alternative to other oral formulations explored for LBC delivery including 
tablets, capsules, and microcapsules 
21
. Potential benefits include low-cost scaleable continuous 
drying, for example utilizing Refractance Window drying 
26,27
. The PFL concept has similarities 
to  orodispersable films used for delivery of small molecule APIs such as rasagiline mesylate or 
tadalafil, used as a substrate for metered drug printing 
41
.  
Although these results indicated that live cell delivery is feasible using PFL, the live cell dose 
achieved, cell phenotype after release, and exact location of live cell release cannot be accurately 
predicted from the simple in vitro dissolution conditions used here. Further in vitro survival and 
release studies are planned using more complex simulated gastrointestinal fluids, for example 
including physiological concentrations of intestinal microbicides such as bile acids 
14,42
. 
Ultimately however, the performance of PFL for therapeutic LBC delivery must be tested by 
determining live cell release in animal models that mimic human GI transit (e.g. using large 
monogastric mammal such as pigs), and therapeutic benefits such as vaccine immunogenicity or 
modulation of GI microbiota using probiotics can only be determined in human clinical studies. 
Conclusions These studies demonstrate the feasibility of a new oral formulation concept for 
simple, effective, controlled enteric delivery and protection from acid of sensitive complex 
biologic payload such as live bacteria for vaccine and probiotic applications. Although maximum 
protection from acid of bacteria dried onto enteric polymer films was achieved when Eudragit 
was blended with ethylcellulose to reduce film permeability in acid, to achieve release of cells 
Eudragit alone was required which fully dissolved at intestinal pH. The release kinetics and 
thereby intestinal release site could be modified by altering the thickness of polymer films used 
to produce PFL, and by altering the lamination method and adhesive used. The therapeutic LBC 
dose, timing and location of release depend on the specific LBC application, with vaccines 
requiring release into the ileum and probiotics benefitting from colonic targeting. Our target 
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critical product attributes were therefore to achieve complete protection from acid, and variable 
kinetics of release to allow controlled LBC targeting. This target was achieved, therapeutically 
relevant dose of 10
8
 CFU of a model attenuated vaccine was released within 1 hour after transfer 
into SIF following 2 hours exposure to SGF. Further studies of PFL are warranted to determine 
stability, viable cell delivery in conditions that fully simulate gastrointestinal transit, and 
ultimately in preclinical models, to determine in vivo cell delivery performance for therapeutic 
live bacteria. 
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FIGURE LEGENDS  
FIGURE 1.Polymer Film Laminate concept. A Diagram of proposed continuous manufacture 
method to produce live bacterial cells dried directly onto pharmaceutical polymer film web. Cells 
mixed with lyoprotectants are spread onto a continuous web of enteric polymer film. B 
Alternative methods for laminating enteric formulations from film dried bacterial cells together 
with enteric polymer film spacers to produce PFL formulations. 
FIGURE 2.Ambient temperature drying live B. breve onto pharmaceutical polymer films. 
(A) Individual drops of cells or evenly spread cell suspension were dried onto cast HPMC films 
at 20ºC in a desiccator and viable cell recovery determined after release into buffered peptone. 
(B) 10L drops of cells were dried onto films cast from either HPMC, Eudragit or Eudragit:EC 
blend (50:50 w/w) and live cell recovery determined after release into buffered peptone 
expressed relative to the cell slurry volume prior to drying. Viable cell density prior to drying 
was measured from samples of cell slurry by plate counting and is indicated by dotted line. Each 
bar represents a single sample of cells dried onto film, and error bars indicate standard deviation 
of 6 replicate cell counts from each sample. Similar recovery after drying was observed in at 
least 3 independent experiments. *: p < 0.05 vs HPMC; ns: not significant. In all groups a 
significant reduction in cell recovery was observed after drying (p < 0.05). 
FIGURE 3.Acid permeability of enteric polymer films. Cast films of Eudragit or Eudragit:EC 
blend (50:50 w/w) were tested for swelling (A) and acid permeability in Franz diffusion cells (B) 
in SGF pH 2.0. A control dialysis membrane was used to confirm rapid acid diffusion to the 
acceptor chamber. (C) Dissolution of replicate samples of films was monitored in SIF pH 7.0. 
Data represent mean values and error bars indicate standard deviation (n=3). 
FIGURE 4. Enteric polymer films can protect dried cells from acid. B. breve cells were dried 
at 26ºC in a desiccator onto films of Eudragit or Eudragit:EC blend. Acid resistance was tested 
by comparing direct release of dried cells into SIF, to direct exposure to SGF, and to exposure of 
the enteric polymer film to acid on the opposite side to the dried cells, followed by release into 
SIF. Data are representative of at least 3 repeat experiments testing acid protection provided by 
enteric polymer films. *: p < 0.05; ns: not significant. In all groups a significant reduction in cell 
recovery was observed after drying (p < 0.05). 
FIGURE 5. Prototype enteric Polymer Film Laminate formulations protect and release 
dried live cells in gastrointestinal conditions. B. breve cells were dried at 26ºC in a desiccator 
onto Eudragit and Eudragit:EC blend films and either kept as film pieces (left “Film”) or made 
into PFL (right “PFL formulation”). Films were released directly into SIF to determine the post-
drying viability (left). PFL formulations were exposed to simulated gastrointestinal conditions by 
immersion in SGF for 2 hours followed by transfer into SIF for 3 hours. Samples were taken at 
indicated times and viable cell recovery determined by plate counting. Each bar represents a 
single PFL formulation with the error bar indicating standard deviation of 6 replicate cell counts. 
Similar viable LBC recovery was observed in 4 different experiments comparing Eudragit with 
Eudragit:EC blend prototype PFL. Viable cell recovery was significantly reduced by drying 
compared to cell slurry before (p < 0.05), but no significant difference was seen after drying 
between Eudragit and Eudraget: EC blend films. 
FIGURE 6. Dye is rapidly released from PFL with varying enteric polymer composition. 
PFL were made from Eudragit or Eudragit:EC blend films containing Water Blue dye, and the 
release kinetics followed in simulated gastrointestinal conditions. Results are representative of 3 
repeats.  
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FIGURE 7. Controlled delivery of probiotic and vaccine live bacterial cells from PFL in 
simulated gastrointestinal conditions. B. breve (A) or S. Typhimurium (B) cells were dried 
onto Eudragit films at 20ºC in a desiccator and PFL were made with varying lamination method 
and adhesive (A) or film thickness (B). Unformulated films were released directly into SIF to 
determine post-drying viability. PFL were immersed in SGF for 2 hours followed by transfer into 
SIF and viable cell recovery determined at indicated timepoints. Each bar represents a single PFL 
formulation with the error bar indicating the standard deviation of 6 replicate cell counts of each 
sample. Similar recovery and kinetics were observed in 3 different experiments with B. breve and 
2 with S. Typhimurium.  
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